Add to my selection

METYRAPONE HRA PHARMA (métyrapone)

Medicine - Posted on Nov 04 2016 - Updated on Jun 12 2019

Active substance (DCI)

métyrapone

history (1)

7/20/16

METYRAPONE HRA PHARMA (metyrapone), treatment of endogenous Cushing’s syndrome and test for pituitary function

Minor improvement in the treatment of endogenous Cushing’s syndrome. No clinical benefit demonstrated as a dynamic test expl...

CAV :
54321

icône flèche

Technical information

ATC code

V04CD01

Manufacturer

HRA PHARMA

Presentation

METYRAPONE HRA PHARMA 250 mg, capsule molle (code CIS : 68806037)
flacon(s) polyéthylène haute densité (PEHD) de 50 capsule(s) - Code CIP : 34009 300 073 2 7

All our publications

Biology (laboratory tests)

Congenital, genetic and rare diseases

Drug therapy

Endocrine system diseases

My account

You do not have a saved search

METYRAPONE HRA PHARMA (métyrapone)

METYRAPONE HRA PHARMA (metyrapone), treatment of endogenous Cushing’s syndrome and test for pituitary function

Follow us :